Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Shareholders' Equity

v3.21.2
Condensed Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Shares
Additional  Paid-In Capital
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Mar. 31, 2020     280,853,000        
Beginning balance at Mar. 31, 2020 $ 965,704 $ 306 $ 281 $ 1,573,347 $ (589,819) $ 306 $ (18,105)
Increase (Decrease) in Partners' Capital [Roll Forward]              
Foreign currency translation (5,134)           (5,134)
Restricted stock units vested (in shares)     806,000        
Restricted stock awards forfeited (in shares)     (96,000)        
Issuance of common stock related to employee stock purchase plan (in shares)     159,000        
Issuance of common stock related to employee stock purchase plan 3,592     3,592      
Exercise of stock options (in shares)     302,000        
Exercise of stock options 4,829     4,829      
Share-based compensation 27,503     27,503      
Equity repurchases (25)     (25)      
Net income 30,344       30,344    
Ending balance (in shares) at Sep. 30, 2020     282,024,000        
Ending balance at Sep. 30, 2020 1,027,119   $ 281 1,609,246 (559,169)   (23,239)
Beginning balance (in shares) at Jun. 30, 2020     281,056,000        
Beginning balance at Jun. 30, 2020 992,784   $ 281 1,589,598 (576,648)   (20,447)
Increase (Decrease) in Partners' Capital [Roll Forward]              
Foreign currency translation (2,792)           (2,792)
Restricted stock units vested (in shares)     674,000        
Restricted stock awards forfeited (in shares)     (8,000)        
Exercise of stock options (in shares)     302,000        
Exercise of stock options 4,829     4,829      
Share-based compensation 14,831     14,831      
Equity repurchases (12)     (12)      
Net income 17,479       17,479    
Ending balance (in shares) at Sep. 30, 2020     282,024,000        
Ending balance at Sep. 30, 2020 $ 1,027,119   $ 281 1,609,246 (559,169)   (23,239)
Beginning balance (in shares) at Mar. 31, 2021 283,130,238   283,130,000        
Beginning balance at Mar. 31, 2021 $ 1,113,601   $ 283 1,653,328 (513,799)   (26,211)
Increase (Decrease) in Partners' Capital [Roll Forward]              
Foreign currency translation 736           736
Restricted stock units vested (in shares)     797,000        
Restricted stock units vested 0   $ 1 (1)      
Restricted stock awards forfeited (in shares)     (19,000)        
Issuance of common stock related to employee stock purchase plan (in shares)     204,000        
Issuance of common stock related to employee stock purchase plan $ 6,593     6,593      
Exercise of stock options (in shares) 913,000   913,000        
Exercise of stock options $ 18,340   $ 1 18,339      
Share-based compensation 44,827     44,827      
Equity repurchases (30)     (30)      
Net income $ 36,935       36,935    
Ending balance (in shares) at Sep. 30, 2021 285,025,237   285,025,000        
Ending balance at Sep. 30, 2021 $ 1,221,002   $ 285 1,723,056 (476,864)   (25,475)
Beginning balance (in shares) at Jun. 30, 2021     284,218,000        
Beginning balance at Jun. 30, 2021 1,158,954   $ 284 1,687,044 (500,505)   (27,869)
Increase (Decrease) in Partners' Capital [Roll Forward]              
Foreign currency translation 2,394           2,394
Restricted stock units vested (in shares)     301,000        
Restricted stock awards forfeited (in shares)     (19,000)        
Exercise of stock options (in shares)     525,000        
Exercise of stock options 10,454   $ 1 10,453      
Share-based compensation 25,575     25,575      
Equity repurchases (16)     (16)      
Net income $ 23,641       23,641    
Ending balance (in shares) at Sep. 30, 2021 285,025,237   285,025,000        
Ending balance at Sep. 30, 2021 $ 1,221,002   $ 285 $ 1,723,056 $ (476,864)   $ (25,475)